S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Alector Stock Forecast, Price & News

-1.36 (-6.39%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
393,344 shs
Average Volume
856,237 shs
Market Capitalization
$1.62 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

Alector logo

About Alector

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.


Alector (NASDAQ:ALEC) Shares Gap Up to $21.16
November 24, 2021 |  americanbankingnews.com
Notable Alector Insider Makes $2.8M Sale - Benzinga
November 15, 2021 |  benzinga.com
Comparing Alector (NASDAQ:ALEC) & ImmunityBio (NASDAQ:IBRX)
November 12, 2021 |  americanbankingnews.com
Alector (NASDAQ:ALEC) Shares Down 5.8% on Insider Selling
November 11, 2021 |  americanbankingnews.com
Alector, Inc. (NASDAQ:ALEC) CEO Sells $2,500,000.00 in Stock
November 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$21.10 million
Book Value
$4.13 per share


Net Income
$-190.23 million
Pretax Margin




Free Float
Market Cap
$1.62 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.37 out of 5 stars

Medical Sector

202nd out of 1,391 stocks

Biological Products, Except Diagnostic Industry

34th out of 201 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Alector (NASDAQ:ALEC) Frequently Asked Questions

Is Alector a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alector stock.
View analyst ratings for Alector
or view top-rated stocks.

How has Alector's stock been impacted by Coronavirus (COVID-19)?

Alector's stock was trading at $24.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALEC stock has decreased by 20.1% and is now trading at $19.92.
View which stocks have been most impacted by COVID-19

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Alector

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) released its quarterly earnings data on Thursday, November, 4th. The company reported $1.49 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $1.95. Alector had a negative net margin of 16.62% and a negative trailing twelve-month return on equity of 12.96%.
View Alector's earnings history

What price target have analysts set for ALEC?

6 equities research analysts have issued twelve-month price targets for Alector's shares. Their forecasts range from $33.00 to $57.00. On average, they anticipate Alector's share price to reach $40.33 in the next twelve months. This suggests a possible upside of 102.5% from the stock's current price.
View analysts' price targets for Alector
or view top-rated stocks among Wall Street analysts.

Who are Alector's key executives?

Alector's management team includes the following people:
  • Arnon Rosenthal, Chief Executive Officer & Director (LinkedIn Profile)
  • Shehnaaz Suliman, President, Chief Operating & Business Officer
  • Linda M. Rubinstein, Chief Financial & Accounting Officer
  • Charles Wolfus, VP-Technology & Digital Health
  • Sam Jackson, Chief Medical Officer

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.52%), EcoR1 Capital LLC (6.15%), Franklin Resources Inc. (2.76%), Geode Capital Management LLC (1.23%), Morgan Stanley (0.99%) and Goldman Sachs Group Inc. (0.73%). Company insiders that own Alector stock include Arnon Rosenthal, Calvin Yu, David M Wehner, Orbimed Advisors Llc, Richard H Scheller, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector

Which institutional investors are selling Alector stock?

ALEC stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Deutsche Bank AG, Citigroup Inc., Pier Capital LLC, Platinum Investment Management Ltd., New York State Common Retirement Fund, California State Teachers Retirement System, and Schonfeld Strategic Advisors LLC. Company insiders that have sold Alector company stock in the last year include Arnon Rosenthal, Calvin Yu, Richard H Scheller, and Robert Paul.
View insider buying and selling activity for Alector
or view top insider-selling stocks.

Which institutional investors are buying Alector stock?

ALEC stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Two Sigma Investments LP, Voloridge Investment Management LLC, Marshall Wace LLP, Morgan Stanley, Millennium Management LLC, UBS Group AG, and BlackRock Inc..
View insider buying and selling activity for Alector
or or view top insider-buying stocks.

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $19.92.

How much money does Alector make?

Alector has a market capitalization of $1.62 billion and generates $21.10 million in revenue each year. The company earns $-190.23 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Alector have?

Alector employs 171 workers across the globe.

What is Alector's official website?

The official website for Alector is www.alector.com.

Where are Alector's headquarters?

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (415) 231-5660 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.